Retinal cells become post-mitotic early during post-natal development. It is likely that p53, a well-known cell cycle regulator, is involved in regulating the genesis, differentiation and death of retinal cells. Furthermore, retinal cells are under constant oxidative stress that can result in DNA damage, due to the extremely high level of metabolic activity associated with phototransduction. If not repaired, this damage may result in p53-dependent cell death and ensuing vision loss. In this study, the role of p53 during retinal development and in the post-mitotic retina is investigated. A previously described super p53 transgenic mouse that expresses an extra copy of the mouse p53 gene driven by its endogenous promoter is utilized. Another transgenic mouse (HIP) that expresses the p53 gene in rod and cone photoreceptors driven by the human interphotoreceptor retinoid binding protein promoter was generated. The electroretinogram (ERG) of the super p53 mouse exhibited reduced rod-driven scotopic a and b wave and cone-driven photopic b wave responses. This deficit resulted from a reduced number of rod photoreceptors and inner nuclear layer cells. However, the reduced photopic signal arose only from lost inner retinal neurons, as cone numbers did not change. Furthermore, cell loss was non-progressive and resulted from increased apoptosis during retinal developmental as determined by TUNEL staining. In contrast, the continuous and specific expression of p53 in rod and cone photoreceptors in the mature retinas of HIP mice led to the selective loss of both rods and cones. These findings strongly support a role for p53 in regulating developmental apoptosis in the retina and suggest a potential role, either direct or indirect, for p53 in the degenerative photoreceptor loss associated with human blinding disorders.
References
[1]
Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749–758.
[2]
Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR (2000) p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 275: 7337–7342.
[3]
Tendler Y, Weisinger G, Coleman R, Diamond E, Lischinsky S, et al. (1999) Tissue-specific p53 expression in the nervous system. Brain Res Mol Brain Res 72: 40–46.
[4]
Shin DH, Lee HY, Lee HW, Kim HJ, Lee E, et al. (1999) In situ localization of p53, bcl-2 and bax mRNAs in rat ocular tissue. Neuroreport 10: 2165–2167.
[5]
Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5: 931–936.
[6]
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7.
[7]
Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, et al. (1999) Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci 40: 1874–1878.
[8]
Schmid P, Lorenz A, Hameister H, Montenarh M (1991) Expression of p53 during mouse embryogenesis. Development 113: 857–865.
[9]
Vuong L, Brobst DE, Saadi A, Ivanovic I, Al-Ubaidi MR (2012) Pattern of expression of p53, its family members, and regulators during early ocular development and in the post-mitotic retina. Invest Ophthalmol Vis Sci 53: 4821–4831.
[10]
Young RW (1985) Cell differentiation in the retina of the mouse. Anat Rec 212: 199–205.
[11]
Vuong L, Conley SM, Al-Ubaidi MR (2012) Expression and Role of p53 in the Retina. Invest Ophthalmol Vis Sci 53: 1362–1371.
[12]
Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, et al. (2002) “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21: 6225–6235.
[13]
Giraldo P, Montoliu L (2001) Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res 10: 83–103.
[14]
Bienz B, Zakut-Houri R, Givol D, Oren M (1984) Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J 3: 2179–2183.
[15]
Tan E, Wang Q, Quiambao AB, Xu X, Qtaishat NM, et al. (2001) The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci 42: 589–600.
[16]
Xu X, Quiambao AB, Roveri L, Pardue MT, Marx JL (2000) Degeneration of cone photoreceptors induced by expression of the Mas1 protooncogene. Exp Neurol 163: 207–219.
[17]
Stricker HM, Ding XQ, Quiambao A, Fliesler SJ, Naash MI (2005) The Cys214–>Ser mutation in peripherin/rds causes a loss-of-function phenotype in transgenic mice. Biochem J 388: 605–613.
[18]
Sherry DM, Murray AR, Kanan Y, Arbogast KL, Hamilton RA, et al. (2010) Lack of protein-tyrosine sulfation disrupts photoreceptor outer segment morphogenesis, retinal function and retinal anatomy. Eur J Neurosci 32: 1461–1472.
[19]
Tan E, Ding XQ, Saadi A, Agarwal N, Naash MI, et al. (2004) Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci 45: 764–768.
[20]
Liou GI, Geng L, Al-Ubaidi MR, Matragoon S, Hanten G, et al. (1990) Tissue-specific expression in transgenic mice directed by the 5′-flanking sequences of the human gene encoding interphotoreceptor retinoid-binding protein. J Biol Chem 265: 8373–8376.
[21]
Baye LM, Link BA (2008) Nuclear migration during retinal development. Brain Res 1192: 29–36.
[22]
Linden R, Rehen SK, Chiarini LB (1999) Apoptosis in developing retinal tissue. Prog Retin Eye Res 18: 133–165.
[23]
Keeler C (1966) Retinal degeneration in the mouse is rodless retina. J Hered 57: 47–50.
[24]
Pittler SJ, Keeler CE, Sidman RL, Baehr W (1993) PCR analysis of DNA from 70-year-old sections of rodless retina demonstrates identity with the mouse rd defect. Proc Natl Acad Sci U S A 90: 9616–9619.
[25]
Drager UC, Hubel DH (1978) Studies of visual function and its decay in mice with hereditary retinal degeneration. J Comp Neurol 180: 85–114.
[26]
Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, et al. (1994) Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 54: 1–5.
[27]
Moll UM, LaQuaglia M, Benard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 92: 4407–4411.
[28]
Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC (1993) Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 54: 693–699.
[29]
Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, et al. (1993) Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin’s lymphoma. Histopathology 22: 39–44.
[30]
Van Veldhuizen PJ, Sadasivan R, Cherian R, Dwyer T, Stephens RL (1993) p53 expression in incidental prostatic cancer. Am J Med Sci 305: 275–279.
[31]
Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 89: 7262–7266.
[32]
Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, et al. (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373.
[33]
Sun XF, Carstensen JM, Stal O, Zhang H, Nilsson E, et al. (1993) Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol 423: 443–448.
[34]
Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127–1130.
[35]
Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH (2001) C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21: 8521–8532.
[36]
Montes de Oca LR, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.
[37]
Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708–713.
[38]
Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714–718.
[39]
Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammerschmidt M (2002) Zebrafish DeltaNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. Dev Cell 2: 617–627.
[40]
Lee H, Kimelman D (2002) A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2: 607–616.
[41]
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99–103.
[42]
Rentzsch F, Kramer C, Hammerschmidt M (2003) Specific and conserved roles of TAp73 during zebrafish development. Gene 323: 19–30.
[43]
Young RW (1985) Cell differentiation in the retina of the mouse. Anat Rec 212: 199–205.
[44]
Berberich T, Kusano T (1997) Cycloheximide induces a subset of low temperature-inducible genes in maize. Mol Gen Genet 254: 275–283.
[45]
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215–221.
[46]
Murray-Zmijewski F, Lane DP, Bourdon JC (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13: 962–972.
[47]
Allocati N, Di IC, De L (2012) V (2012) p63/p73 in the control of cell cycle and cell death. Exp Cell Res 318: 1285–1290.
[48]
Jackson MW, Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20: 1001–1007.
